Phase I Testing of a Malaria Vaccine Composed of Hepatitis B Virus Core Particles ExpressingPlasmodium falciparumCircumsporozoite Epitopes
| Autor: | Giane A. Oliveira, Michael L. Corado, Elizabeth Nardin, Ashley J. Birkett, George B. Thornton, Kristiane Wetzel, Annette Schmidt, Carolin Maier, Pramod Sarpotdar, J. Mauricio Calvo-Calle |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Adult
Adolescent T-Lymphocytes Molecular Sequence Data Plasmodium falciparum Immunology Protozoan Proteins Antibodies Protozoan medicine.disease_cause Microbiology Epitope Epitopes Interferon-gamma Double-Blind Method Orthohepadnavirus Malaria Vaccines parasitic diseases medicine Animals Humans Amino Acid Sequence Malaria Falciparum Hepatitis B virus Vaccines Synthetic biology Malaria vaccine Immunogenicity Virion Middle Aged Hepatitis B medicine.disease biology.organism_classification Hepatitis B Core Antigens Virology Infectious Diseases Hepadnaviridae Microbial Immunity and Vaccines Alum Compounds Parasitology |
| Zdroj: | Infection and Immunity. 72:6519-6527 |
| ISSN: | 1098-5522 0019-9567 |
| DOI: | 10.1128/iai.72.11.6519-6527.2004 |
| Popis: | We report the first phase I trial to assess the safety and immunogenicity of a malaria vaccine candidate, ICC-1132 (Malarivax), composed of a modified hepatitis B virus core protein (HBc) containing minimal epitopes of thePlasmodium falciparumcircumsporozoite (CS) protein. When expressed inEscherichia coli, the recombinant ICC-1132 protein forms virus-like particles that were found to be highly immunogenic in preclinical studies of mice and monkeys. Twenty healthy adult volunteers received a 20- or a 50-μg dose of alum-adsorbed ICC-1132 administered intramuscularly at 0, 2, and 6 months. The majority of volunteers in the group receiving the 50-μg dose developed antibodies to CS repeats as well as to HBc. Malaria-specific T cells that secreted gamma interferon were also detected after a single immunization with ICC-1132-alum. These studies support ICC-1132 as a promising malaria vaccine candidate for further clinical testing using more-potent adjuvant formulations and confirm the potential of modified HBc virus-like particles as a delivery platform for vaccines against other human pathogens. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|